Compare Danaher Corporation (DHR) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Marsh & McLennan Companies, Inc. — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: Danaher Corporation is the larger of the two by market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| DHR | MRSH | |
|---|---|---|
Market Cap | $152.87B | $84.31B |
Volume | 5,228,698 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $242.05 | $207.02 |
52-Week Low | $161.91 | $157.32 |
Typical Hold Time | 69 Days | 109 Days |
Enterprise Value | $175.08B | $104.99B |
Dividend Yield | 0.74% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Marsh (MRSH) trades at $176.67, up 1.73% today, with a bullish technical trend and strong support at $174. The company shows robust fundamentals, with revenue growing to $26.98B in 2025 and a net income margin of 14.24%. Recent acquisition of Accel Holdings (Business Wire, 2026-10-02) may enhance growth. Earnings have consistently beaten estimates in recent quarters, with Q3 2026 results pending.
Outlook is positive with a consensus price target of $202.71 (MarketBeat, 2026-09-30), offering ~15% upside. Risks include competitive pressures and market volatility. Analyst sentiment is mixed, with 32% buy ratings but 65% hold, suggesting cautious optimism amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
